PhaseBio Pharmaceuticals Inc (PHAS) is near the top in its industry group according to InvestorsObserver. PHAS gets an overall rating of 45. That means it scores higher than 45 percent of stocks. PhaseBio Pharmaceuticals Inc gets a 74 rank in the Biotechnology industry. Biotechnology is number 111 out of 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
What's Happening With PhaseBio Pharmaceuticals Inc Stock Today?
PhaseBio Pharmaceuticals Inc (PHAS) stock has fallen -0.55% while the S&P 500 has gained 0.14% as of 10:46 AM on Thursday, Jun 17. PHAS is down -$0.02 from the previous closing price of $3.95 on volume of 1,828,232 shares. Over the past year the S&P 500 is up 35.85% while PHAS is down -19.96%. PHAS lost -$3.74 per share the over the last 12 months.
Click Here to get the full Stock Score Report on PhaseBio Pharmaceuticals Inc (PHAS) Stock.
